Ryan Deschner
Stock Analyst at Jefferies
(4.58)
# 190
Out of 4,873 analysts
12
Total ratings
63.64%
Success rate
42.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INZY Inozyme Pharma | Downgrades: Hold | $15 → $4 | $3.99 | +0.25% | 2 | May 16, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Outperform | $75 → $52 | $18.39 | +182.76% | 1 | May 9, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $27 → $29 | $13.60 | +113.24% | 3 | May 9, 2025 | |
| TRVI Trevi Therapeutics | Upgrades: Strong Buy | $9 → $29 | $5.68 | +410.56% | 2 | Mar 10, 2025 | |
| ARDX Ardelyx | Reiterates: Strong Buy | $15 → $13 | $3.63 | +258.13% | 1 | Feb 21, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $17.26 | +62.22% | 3 | Jan 14, 2025 |
Inozyme Pharma
May 16, 2025
Downgrades: Hold
Price Target: $15 → $4
Current: $3.99
Upside: +0.25%
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Outperform
Price Target: $75 → $52
Current: $18.39
Upside: +182.76%
Liquidia
May 9, 2025
Maintains: Strong Buy
Price Target: $27 → $29
Current: $13.60
Upside: +113.24%
Trevi Therapeutics
Mar 10, 2025
Upgrades: Strong Buy
Price Target: $9 → $29
Current: $5.68
Upside: +410.56%
Ardelyx
Feb 21, 2025
Reiterates: Strong Buy
Price Target: $15 → $13
Current: $3.63
Upside: +258.13%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $17.26
Upside: +62.22%